Particle.news
Get it on Google Play
Download on the App Store
4 ARTICLES
·
20h ago

Study Shows Epstein‑Barr Virus Provokes CD4+ T‑Cell Attack Linked to Multiple Sclerosis

The finding points to antivirals or vaccines that target active EBV as a possible way to prevent or treat MS without lifelong immune suppression.

Using the fluorescent antibody (FA) staining technique, this photomicrograph revealed the cumulative effect of the Epstein-Barr virus on cells of unknown origin. EBV is a member of the Herpesvirus family, and is one of the most common human viruses. When infection with EBV occurs during adolescence, or young adulthood, it causes infectious mononucleosis 35% to 50% of the time. EBV has also been determined to be a cause of Burkitt’s lymphoma and nasopharyngeal carcinoma.
A scanning electron micrograph of immune cells called microglial cells (round) ingesting specialised cells called oligodendrocytes (branched) that maintain the myelin sheath around nerves, which is thought to occur in multiple sclerosis
Image
Image

Overview

  • Researchers reported on July 15, 2026 that people with untreated multiple sclerosis have about twice as many CD4+ T cells that target EBV proteins made during active viral replication and roughly 2.5 times more detectable EBV than controls.
  • The multi‑site study measured T cells and saliva from cohorts in Boston, Baltimore and Bergen and found that these CD4+ cells preferentially recognize lytic EBV proteins that could drive immune attacks on nerve insulation.
  • Patients given B‑cell‑depleting anti‑CD20 therapies showed an about 2.5‑fold fall in the EBV‑specific CD4+ T‑cell response and a marked drop or loss of detectable EBV in saliva, offering a mechanistic reason those drugs work.
  • The results strengthen the case for developing EBV‑targeted antivirals and vaccines as more specific options, though such products remain experimental and unproven for preventing or treating MS.
  • EBV infects roughly 90% of adults while MS affects about 2.9 million people worldwide, so researchers say the next steps are clinical trials of antivirals and vaccines and studies to show whether lowering EBV activity changes patients’ long‑term outcomes.